BRAF, a member of a serine/threonine kinase protein family, serves as an immediate downstream effector of RAS in the MAPK signaling cascade, a signal transduction pathway that transmits mitogenic ...

Surprisingly, this process does not rely on reactivating the BRAF-ERK pathway, which is the usual resistance mechanism. Using cutting-edge mass spectrometry-based phosphoproteomics and deep ...

Opens in a new tab or window The group highlights major advances in understanding the biology of these tumors, particularly the central role of MAP kinase pathway alterations -- most notably BRAF ...

Surprisingly, this process does not rely on reactivating the BRAF-ERK pathway, which is the usual resistance mechanism. Using cutting-edge mass spectrometry-based phosphoproteomics and deep ...

but also sensitizes the tumors to specific inhibitors of pathway components. As we have reported, the BRAF and RAS mutant tumors are more sensitive to ERK pathway inhibition than the RAF/RAS wild type ...

Surprisingly, this process does not rely on reactivating the BRAF-ERK pathway, which is the usual resistance mechanism. Using cutting-edge mass spectrometry-based phosphoproteomics and deep ...

Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose ...